AI Meets Gene Editing: the Path to Plug-and-Play Drug Development
AI is no panacea, but it can have a role in turning artisanal, trial-and-error drug development into a rapid, cost-effective, data-driven process.
Felix Dobbs
Felix Dobbs is a co-founder and the CEO of Broken String Biosciences. He is the primary inventor of Broken String’s DNA break mapping technology INDUCE-seq™, and holds an AstraZeneca-sponsored PhD in CRISPR genome editing and genomics from Cardiff University.